Study of a New Anti-HIV Drug, T-20, in HIV-Infected Children
Completed
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Phase 1
1969-12-31
The purpose of this study is to determine the best dose of T-20, a new anti-HIV drug, to
treat HIV-infected children.
T-20, unlike other anti-HIV medications, lessens the ability of HIV to infect certain cells
(T cells) in the body. Doctors hope to better treat HIV by adding T-20 to anti-HIV drug
combinations that include 1 or 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus a
nonnucleoside reverse transcriptase inhibitor (NNRTI) and/or a protease inhibitor (PI).
Study of a New Anti-HIV Drug, T-20, in HIV-Infected Children
Completed
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 1
1969-12-31
The purpose of this study is to determine the best dose of T-20, a new anti-HIV drug, to
treat HIV-infected children.
T-20, unlike other anti-HIV medications, lessens the ability of HIV to infect certain cells
(T cells) in the body. Doctors hope to better treat HIV by adding T-20 to anti-HIV drug
combinations that include 1 or 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus a
nonnucleoside reverse transcriptase inhibitor (NNRTI) and/or a protease inhibitor (PI).
A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults
Completed
Trimeris
Phase 2
1999-05-01
The purpose of this study is to see if it is safe and effective to give T-20, a new type of
anti-HIV drug, with a combination of other anti-HIV drugs. The other anti-HIV drugs used are
abacavir (ABC), amprenavir (APV), ritonavir (RTV), and efavirenz (EFV). Three different doses
of T-20 are tested.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
